Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10020922 | 0.88 | MEN1 (0.41) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL10020919 | 0.85 | MEN1 (0.40) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL10020926 | 0.81 | MEN1 (0.40) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL10020924 | 0.81 | MEN1 (0.40) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL10052141 | 0.80 | MEN1 (0.43) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL10020916 | 0.79 | MEN1 (0.42) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL10020914 | 0.79 | MEN1 (0.42) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL10020931 | 0.78 | MEN1 (0.48) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL10020921 | 0.76 | MEN1 (0.43) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL10020920 | 0.69 | MEN1 (0.51) | MEN1USP2POLBPPARGBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101655-B2 | Fluorescent dyes and complexes | SMITH GERALD ARTHUR (GB) | 2012-01-24 | — | — | US | disclosed |
| US-20100256399-A1 | FLUORESCENT DYES AND COMPLEXES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-10-07 | — | — | US | disclosed |
| US-7674918-B2 | Fluorescent dyes and complexes | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-20070238884-A1 | Fluorescent Dyes and Complexes | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238884-A1 | Fluorescent Dyes and Complexes | F12, PYM1, ANXA6 | MEN1 3023/4885USP2 4580/4885POLB 4081/4885 |
| US-20100256399-A1 | FLUORESCENT DYES AND COMPLEXES | F12, ANXA6, PYM1 | MEN1 2188/4885USP2 4698/4885POLB 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.